Pivot point:  Efforts shift from vaccine to tracking origin of coronavirus

Pivot point: Efforts shift from vaccine to tracking origin of coronavirus


With cases soaring in the United States and elsewhere, the Covid-19 pandemic is nowhere near its end – but with three vaccines reporting trial data and two apparently nearing approval by the US Food and Drug Administration, it may be reaching a pivot point.

In what feels like a moment of drawing breath and taking stock, international researchers are turning their attention from the present back to the start of the pandemic, aiming to untangle its origin and asking what lessons can be learned to keep this from happening again.

Two efforts are happening in parallel. On November 5, the World Health Organisation (WHO) quietly published the rules of engagement for a long-planned and months-delayed mission that creates a multinational team of researchers who will pursue how the virus leaped species.

Meanwhile, last week, a commission created by The Lancet and headed by the economist and policy expert Jeffrey Sachs announced the formation of its own international effort, a taskforce of 12 experts from nine countries who will undertake similar tasks.

Both groups will face the same complex problems. It has been approximately a year since the first cases of a pneumonia of unknown origin appeared in Wuhan, China, and about 11 months since the pneumonia’s cause was identified as a novel coronavirus, probably originating in bats.

The experts will have to retrace a chain of transmission – one or multiple leaps of the virus from the animal world into humans – using interviews, stored biological samples, lab assays, environmental surveys, genomic data and the thousands of papers published since the pandemic began, all while following a trail that may have gone cold.

The point is not to look for patient zero, the first person infected – or even a hypothetical bat zero, the single animal from which the novel virus jumped. It is likely neither of those will ever be found. The goal instead is to elucidate the ecosystem – physical, but also viral – in which the spillover happened and ask what could make it likely to happen again.

“This is not a simple case of going to a market and picking up samples and testing,” says Peter Daszak, the president of the nonprofit research organization EcoHealth Alliance, who leads the Lancet commission task force.

“This is about what’s been changing on the ground in the region, in terms of the ecology of viruses and the social science of contact with wildlife – going back to SARS – and asking what research was done that could have been used to protect us, and was done or was not.”

The effort isn’t going to resemble movie-style moonsuit-clad narratives of disease detection, Daszak says – not least because, as of now, the teams still can’t travel to China. And, intellectually, it won’t proceed like them, either.

“There’s a disconnect between what the public thinks goes on in missions like this and what can be done,” he says. “There’s an expectation of holding up a magnifying glass and finding the smoking gun, a criminal law approach. But we’re never going beyond a reasonable doubt with the origins of Covid. Science doesn’t work like that. Science works on the civil law approach: Where does the preponderance of evidence fit?”

Sachs, who chose Daszak to chair the taskforce, agrees. The goal, he wrote by email, is not “a forensic investigation … It is a scientific assessment.”

“The team will review the global literature comprehensively and from multiple perspectives (ecology, virology, public health practices), and will do its best to engage with China’s public health leaders and scientists,” he said. “The team will also invite inputs from those who would like to submit information or who have advanced particular theories or possibilities about the origins of SARS-CoV-2.”

The obstacles are formidable and that is before the teams tangle with the politics of the disease. The Trump administration, of course, has made the pandemic political, persistently calling the novel coronavirus the “China virus.”

In the spring, President Donald Trump and Secretary of State Mike Pompeo pushed theories that the virus was the result of a Wuhan lab accident and possibly human-made.

The US intelligence community rebuked that theory in April.

Despite that refutation – and protests from the WHO and from Asian Americans – the White House continued to stigmatise China’s connection to the virus’s emergence. In fact, a peer-reviewed $3.7 million National Institutes of Health grant to Daszak’s organisation was taken away last April after the White House discovered that EcoHealth Alliance collaborates with the Wuhan Institute of Virology.

But the government of China has also used scientific findings for political purposes. Chinese scientists recently aired theories that the virus was imported into the country in frozen food, and also that it was circulating on other continents months before appearing in Wuhan.

And it is not at all clear that China will allow either team in. WHO effort has been in planning stages since February. In October, Michael Ryan, executive director of its health emergencies programme, disclosed that the mission will have two phases, one conducted in China by Chinese researchers and a second involving the multinational team.

The Lancet effort could equally be hobbled by politics or by the restrictions on movement imposed by the pandemic itself.

Meanwhile, new pieces of research keep suggesting reframings of the origin story. Early last week, scientists at the US Centers for Disease Control and Prevention wrote in Clinical Infectious Diseases that they have identified antibodies to SARS CoV-2 in samples of donated blood collected on the US West Coast from December 13-16, 2019.

If their observation is correct, it would mean the virus was present in the US as the first cases were being found in China and a full month before the first known US case. Researchers in France have found molecular evidence of the virus in a sputum sample taken from a man hospitalised on December 27, 2019.

And Italian scientists recently announced they have found antibodies in blood samples taken during lung-cancer screenings as far back as September 2019.

  • A Wired report
About author

Your email address will not be published. Required fields are marked *